Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Urwyler

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Medicine|October 28, 2023
Risk Factors for Recurrent Exacerbations in the General-Practitioner-Based Swiss Chronic Obstructive Pulmonary Disease (COPD) CohortNebal S Abu Hussein, Stephanie Giezendanner, Pascal Urwyler, et al.
Multidisciplinary Respiratory Medicine|February 19, 2019
Predictive factors for exacerbation and re-exacerbation in chronic obstructive pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohortPascal Urwyler, Nebal Abu Hussein, Pierre O Bridevaux, et al.
Antimicrobial Resistance and Infection Control|June 3, 2026
Two clusters of carbapenemase-producing bacteria linked to hospital utility room wastewater drains - an outbreak reportIsabelle Vock, Gioele Capoferri, Sabine Kuster, et al.
Trials|January 5, 2021
Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)Pascal Urwyler, Panteleimon Charitos, Stephan Moser, et al.
Frontiers in Immunology|November 15, 2023
Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trialPascal Urwyler, Marina Leimbacher, Panteleimon Charitos, et al.
Emerging Infectious Diseases|December 23, 2024
Toxigenic Corynebacterium diphtheriae Infections in Low-Risk Patients, Switzerland, 2023Pascal Urwyler, Daniel Goldenberger, Kerstin Grosheintz, et al.
Swiss Medical Weekly|December 13, 2017
Feasibility, acceptability and effectiveness of integrated care for COPD patients: a mixed methods evaluation of a pilot community-based programmeTania Carron, Pierre-Olivier Bridevaux, Karin Lörvall, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Medicine|October 28, 2023
Risk Factors for Recurrent Exacerbations in the General-Practitioner-Based Swiss Chronic Obstructive Pulmonary Disease (COPD) CohortNebal S Abu Hussein, Stephanie Giezendanner, Pascal Urwyler, et al.
Multidisciplinary Respiratory Medicine|February 19, 2019
Predictive factors for exacerbation and re-exacerbation in chronic obstructive pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohortPascal Urwyler, Nebal Abu Hussein, Pierre O Bridevaux, et al.
Antimicrobial Resistance and Infection Control|June 3, 2026
Two clusters of carbapenemase-producing bacteria linked to hospital utility room wastewater drains - an outbreak reportIsabelle Vock, Gioele Capoferri, Sabine Kuster, et al.
Trials|January 5, 2021
Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)Pascal Urwyler, Panteleimon Charitos, Stephan Moser, et al.
Frontiers in Immunology|November 15, 2023
Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trialPascal Urwyler, Marina Leimbacher, Panteleimon Charitos, et al.
Emerging Infectious Diseases|December 23, 2024
Toxigenic Corynebacterium diphtheriae Infections in Low-Risk Patients, Switzerland, 2023Pascal Urwyler, Daniel Goldenberger, Kerstin Grosheintz, et al.
Swiss Medical Weekly|December 13, 2017
Feasibility, acceptability and effectiveness of integrated care for COPD patients: a mixed methods evaluation of a pilot community-based programmeTania Carron, Pierre-Olivier Bridevaux, Karin Lörvall, et al.
Pageof 2